{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Activated+Protein+C", "query": { "intervention": "Activated Protein C" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 69, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Activated+Protein+C&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T00:58:10.403Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04493203", "title": "Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yana Najjar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2020-12-18", "completion_date": "2025-04-12", "has_results": true, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-09-13T00:58:10.403Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493203" }, { "nct_id": "NCT02443077", "title": "Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type" ], "interventions": [ { "name": "Autologous Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Placebo Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2016-10-12", "completion_date": "2026-12-23", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-13T00:58:10.403Z", "location_count": 280, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 202 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02443077" }, { "nct_id": "NCT05789524", "title": "The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hemophilia a", "Hemophilia B" ], "interventions": [ { "name": "SerpinPC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ApcinteX Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "12 Years to 65 Years · Male only" }, "enrollment_count": 60, "start_date": "2023-07-06", "completion_date": "2025-02-28", "has_results": false, "last_update_posted_date": "2025-03-11", "last_synced_at": "2026-09-13T00:58:10.403Z", "location_count": 10, "location_summary": "Aurora, Colorado • Tampa, Florida • Indianapolis, Indiana + 7 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05789524" }, { "nct_id": "NCT05800015", "title": "A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "fianlimab", "type": "DRUG" }, { "name": "cemiplimab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2023-08-08", "completion_date": "2031-12-23", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-13T00:58:10.403Z", "location_count": 29, "location_summary": "Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05800015" }, { "nct_id": "NCT02061761", "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "BMS-986016", "type": "BIOLOGICAL" }, { "name": "BMS-936558", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2014-03-13", "completion_date": "2022-02-16", "has_results": true, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-09-13T00:58:10.403Z", "location_count": 8, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 5 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02061761" }, { "nct_id": "NCT02627274", "title": "A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Breast Cancer", "Cancer of Head and Neck" ], "interventions": [ { "name": "RO6874281", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2015-12-07", "completion_date": "2022-11-10", "has_results": false, "last_update_posted_date": "2022-11-22", "last_synced_at": "2026-09-13T00:58:10.403Z", "location_count": 5, "location_summary": "Tucson, Arizona • La Jolla, California • Greeley, Colorado + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Greeley", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02627274" }, { "nct_id": "NCT00028275", "title": "Gamma Interferon Therapy for Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Gamma Interferon 1b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 20, "start_date": "2001-12", "completion_date": "2003-11", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-09-13T00:58:10.403Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028275" }, { "nct_id": "NCT01025531", "title": "Cell Bound Complement Activation Proteins as Markers of Liver Injury", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C" ], "interventions": [], "intervention_types": [], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2008-12", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2014-12-08", "last_synced_at": "2026-09-13T00:58:10.403Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01025531" }, { "nct_id": "NCT05010707", "title": "Transgender Estradiol Affirming Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transgenderism" ], "interventions": [ { "name": "Transdermal patch", "type": "DRUG" }, { "name": "Pro-thrombotic markers", "type": "DIAGNOSTIC_TEST" }, { "name": "Metabolic markers", "type": "DIAGNOSTIC_TEST" }, { "name": "Hormone Profile", "type": "DIAGNOSTIC_TEST" }, { "name": "Daily Sublingual Tablet", "type": "DRUG" }, { "name": "BID Sublingual Tablet", "type": "DRUG" }, { "name": "Spironolactone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "30 Years", "sex": "MALE", "summary": "18 Years to 30 Years · Male only" }, "enrollment_count": 39, "start_date": "2021-08-02", "completion_date": "2024-01-01", "has_results": true, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-09-13T00:58:10.403Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05010707" }, { "nct_id": "NCT05789537", "title": "A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hemophilia B with Inhibitor", "Hemophilia B" ], "interventions": [ { "name": "SerpinPC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ApcinteX Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "12 Years to 65 Years · Male only" }, "enrollment_count": 3, "start_date": "2023-07-28", "completion_date": "2025-02-24", "has_results": false, "last_update_posted_date": "2025-03-11", "last_synced_at": "2026-09-13T00:58:10.403Z", "location_count": 3, "location_summary": "Aurora, Colorado • Tampa, Florida • Greenville, North Carolina", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Greenville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05789537" } ] }